A version of this digest first appeared in the weekly STAT Health Tech newsletter. To receive future editions, sign up here.

Let’s start with a briefing on rapid financial maneuvering right now in the telehealth industry, and the significant risks that underlie it.

To catch you up: The nation’s largest telehealth companies are making big bets on a surge in demand amid the Covid-19 pandemic. Teladoc, the largest provider, is acquiring the online chronic disease company Livongo in an $18.5 billion deal, and AmwellMDLive, and GoodRx — which operates a telehealth business called HeyDoctor — are all preparing for initial public offerings. The paperwork for those IPOs offer a new window into the long-murky picture of finances in telemedicine, as Rebecca explains in a new story that digs into the filings.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy